For instance, simvastatin has been observed to enhance the prognosis of NASH-related fibrosis by modulating the expression of endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) while inhibiting the activation of HSCs [93]. This evidence concerns the gene NOS3 and metabolic dysfunction-associated steatohepatitis.